Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 4, 2009, Pages 431-436

  Nielsen, Trine R ^a   Rostgaard, K ^a   Askling, J ^b   Steffensen, R ^c   Oturai, A ^d   Jersild, C ^e   Koch Henriksen, N ^c,f   Sorensen P S ^d   Hjalgrim, H ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d Mental Health Services CPH   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

15; Epidemiology; HLA DRB1; Immunology; Infectious mononucleosis; Multiple sclerosis

Indexed keywords

HLA DR2 ANTIGEN;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; INFECTIOUS MONONUCLEOSIS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR;

GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HUMANS; INFECTIOUS MONONUCLEOSIS; MULTIPLE SCLEROSIS; PREVALENCE; RISK FACTORS;

EID: 63149116383     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508100037     Document Type: Article

References (38)

1. Jersild, C, Fog, T, Hansen, GS, Thomsen, M, Svejgaard, A, Dupont, B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973; 2: 1221-1225.
2. Beall, SS, Biddison, WE, McFarlin, DE, McFarland, HF, Hood, LE. Susceptibility for multiple sclerosis is determined, in part, by inheritance of a 175-kb region of the TcR V beta chain locus and HLA class II genes. J Neuroimmunol 1993; 45: 53-60.
3. de Jong, BA, Huizinga, TW, Zanelli, E, et al. Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region. Neurology 2002; 59: 549-555.
4. Olerup, O, Hillert, J. HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation. Tissue Antigens 1991; 38: 1-15.
5. Hafler, DA, Compston, A, Sawcer, S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
6. Nielsen, TR, Rostgaard, K, Nielsen, NM, et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007; 64: 72-75.
7. Levin, LI, Munger, KL, Rubertone, MV, et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293: 2496-2500.
8. Operskalski, EA, Visscher, BR, Malmgren, RM, Detels, R. A case-control study of multiple sclerosis. Neurology 1989; 39: 825-829.
9. Lindberg, C, Andersen, O, Vahlne, A, Dalton, M, Runmarker, B. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology 1991; 10: 62-65.
10. Martyn, CN, Cruddas, M, Compston, DA. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 167-168.
11. Haahr, S, Koch-Henriksen, N, Moller-Larsen, A, Eriksen, LS, Andersen, HM. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: A historical prospective study. Mult Scler 1995; 1: 73-77.
12. Marrie, RA, Wolfson, C, Sturkenboom, MC, et al. Multiple sclerosis and antecedent infections: A case-control study. Neurology 2000; 54: 2307-2310.
13. Hernan, MA, Zhang, SM, Lipworth, L, Olek, MJ, Ascherio, A. Multiple sclerosis and age at infection with common viruses. Epidemiology 2001; 12: 301-306.
14. Haahr, S, Plesner, AM, Vestergaard, BF, Hollsberg, P. A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurol Scand 2004; 109: 270-275.
15. Goldacre, MJ, Wotton, CJ, Seagroatt, V, Yeates, D. Multiple sclerosis after infectious mononucleosis: Record linkage study. J Epidemiol Community Health 2004; 58: 1032-1035.
16. Lang, HL, Jacobsen, H, Ikemizu, S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3: 940-943.
17. Koch-Henriksen, N. The Danish Multiple Sclerosis Registry: A 50-year follow-up. Mult Scler 1999; 5: 293-296.
18. Fagius, J. [Disease-modifying treatment of MS-progress with complications] Lakartidningen 2003; 100: 1164, 1167-1168.
19. Hjalgrim, H, Askling, J, Sorensen, P, et al. Risk of Hodgkin's disease and other cancers after infectious mononucleosis. J Natl Cancer Inst 2000; 92: 1522-1528.
20. Oturai, A, Larsen, F, Ryder, LP, et al. Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis. Ann Neurol 1999; 46: 612-616.
21. Akesson, E, Oturai, A, Berg, J, et al. A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. Genes Immun 2002; 3: 279-285.
22. Dunbar, SA. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta 2006; 363: 71-82.
23. Piegorsch, WW, Weinberg, CR, Taylor, JA. Nonhierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med 1994; 13: 153-162.
24. De Jager, PL, Simon, KC, Munger, KL, Rioux, JD, Hafler, DA, Ascherio, A. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008; 70: 1113-1118.
25. Nielsen, TR, Pedersen, M, Rostgaard, K, Frisch, M, Hjalgrim, H. Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. Mult Scler 2007; 13: 420-423.
26. Ascherio, A, Munger, KL, Lennette, ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study. JAMA 2001; 286: 3083-3088.
27. DeLorenze, GN, Munger, KL, Lennette, ET, Orenstreich, N, Vogelman, JH, Ascherio, A. Epstein-Barr virus and multiple sclerosis: Evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006; 63: 839-844.
28. Larsen, PD, Bloomer, LC, Bray, PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985; 35: 435-438.
29. Oldstone, MB. Molecular mimicry and autoimmune disease. Cell 1987; 50: 819-820.
30. Ythier, A, Moreau, JF, Peyrat, MA, Bignon, JD, Soulillou, JP. HLA-AB and -DR types in patients with infectious mononucleosis (IM). Tissue Antigens 1983; 21: 329-332.
31. Ebers, GC. Prognostic factors for multiple sclerosis: The importance of natural history studies. J Neurol 2005; 252(Suppl. 3): Iii15-iii20.
32. Masterman, T, Ligers, A, Olsson, T, Andersson, M, Olerup, O, Hillert, J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000; 48: 211-219.
33. Hensiek, AE, Sawcer, SJ, Feakes, R, et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 184-187.
34. Smestad, C, Brynedal, B, Jonasdottir, G, et al. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007; 14: 835-840.
35. Kantarci, OH. de, AM, Weinshenker, BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002; 123: 144-159.
36. Edgren, G, Tran, TN, Hjalgrim, H, et al. Improving health profile of blood donors as a consequence of transfusion safety efforts. Transfusion 2007; 47: 2017-2024.
37. Tiitinen, S, Kaarela, K, Filipowicz-Sosnowska, A, et al. HLA typing and seropositivity in Finnish and in Polish patients with rheumatoid arthritis and amyloidosis. Clin Rheumatol 1992; 11: 265-268.
38. Schipper, RF, D'Amaro, J, Bakker, JT, Bakker, J, van Rood, JJ, Oudshoorn, M. HLA gene haplotype frequencies in bone marrow donors worldwide registries. Hum Immunol 1997; 52: 54-71.